| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
Eleutheroside C interacts with multiple molecular targets including heat shock protein 90 alpha family class A member 1 (HSP90AA1), signal transducer and activator of transcription 3 (STAT3), vascular endothelial growth factor A (VEGFA), and matrix metalloproteinase 9 (MMP9). These targets are involved in various biological processes including inflammation, cell proliferation, angiogenesis, and tissue remodeling. The compound has also been shown to interact with MurA enzyme, a critical target for antibacterial agents, with superior binding affinity (-10.5 kcal/mol) compared to fosfomycin (-4.6 kcal/mol).
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that Eleutheroside C exhibits antibacterial activity against various pathogens. It has been shown to stimulate peripheral opioid receptors, resulting in decreased plasma glucose in insulin-dependent diabetic rats. The compound exerts antifatigue effects by lowering plasma triglycerides, lactate dehydrogenase, and blood urea nitrogen, suggesting a decrease in muscle damage from intense physical exertion. It also exhibits antioxidative effects and may interact with various neurotransmitter systems. In silico studies have predicted its potential antibacterial mechanism via MurA enzyme inhibition.
|
| ln Vivo |
In vivo studies in animal models demonstrate Eleutheroside C's anti-fatigue and metabolic effects. The compound improves stamina by enabling skeletal muscle to better utilize lipids and spare glycogen, thereby reducing lactic acid buildup and increasing oxygen saturation and blood glucose and free fatty acid availability during heavy exertion. It regulates tyrosine metabolism, mitochondrial oxidation of long-chain saturated fatty acids, fatty acid metabolism, methionine metabolism, and sphingolipid metabolism. These effects lead to improved lipid utilization and boosted cardiovascular metabolism.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Eleutheroside C typically use purified target proteins or membrane preparations. For MurA enzyme binding studies, the compound's affinity is measured using surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC) to determine binding kinetics and thermodynamics. For other targets such as HSP90AA1, STAT3, VEGFA, and MMP9, standard radioligand binding or fluorescence polarization assays can be employed. Competition binding experiments are performed with varying concentrations of Eleutheroside C and appropriate labeled ligands. IC50 and Ki values are calculated from dose-response curves.
|
| Cell Assay |
In vitro cell-based assays for Eleutheroside C are conducted using various cell lines depending on the target of interest. Cells are cultured in appropriate media and treated with varying concentrations of the compound (typically 1-100 microM) for 24-72 hours. Cellular effects assessed include cell viability (MTT assay), proliferation, apoptosis, and inflammatory marker expression. Antibacterial activity is evaluated using standard broth microdilution methods to determine minimum inhibitory concentrations (MICs) against Gram-positive and Gram-negative bacteria. The compound's effects on cellular signaling pathways are assessed by Western blotting for phosphorylated proteins.
|
| Animal Protocol |
In vivo animal studies for Eleutheroside C typically use rodent models. For anti-fatigue studies, mice or rats are administered the compound orally or intraperitoneally at doses of 10-100 mg/kg for 1-4 weeks. Exercise capacity is assessed using forced swimming tests or treadmill running tests. Blood samples are collected for biochemical analysis including glucose, lactate, triglycerides, lactate dehydrogenase, blood urea nitrogen, and free fatty acids. Tissue samples (liver, muscle) are collected for histology and metabolic analysis. For antibacterial studies, infected animal models are used to evaluate in vivo efficacy.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Eleutheroside C are characteristic of small glycoside compounds. With a molecular weight of 208.21 and a galactoside structure, the compound is likely to have good water solubility but moderate oral bioavailability due to potential gastrointestinal metabolism. It is liposoluble and likely to be readily absorbed and distributed in the body. The compound's stability and efficacy can be affected by factors such as pH, temperature, and light exposure. Storage at 4degC protected from light is recommended. Standard pharmacokinetic parameters (Cmax, Tmax, AUC, half-life) can be determined following oral or intravenous administration in animal models.
|
| Toxicity/Toxicokinetics |
Toxicological data for Eleutheroside C are limited to preclinical studies. As a naturally occurring glycoside, it is generally considered to have low toxicity at pharmacological doses. The compound is intended for research use only and not for human therapeutic applications. Acute and chronic toxicity studies have not been systematically reported in the literature. Standard safety precautions for handling chemical compounds apply. Storage recommendations: 4degC, protected from light. Not approved for clinical use.
|
| References | |
| Additional Infomation |
1-Ethyl-β-D-galactoside is a glycoside. It has been reported that eleutheroside C is found in Rubus sylvestris, Agave amikania, and Agave davidii, and relevant data are available.
Eleutheroside C is a research-grade natural product glycoside isolated from plant sources. Its synonyms include Ethyl alpha-D-galactoside and Ethyl alpha-D-galactopyranoside. The compound has a purity of ≥98% (HPLC) and appears as a white to off-white powder. It is classified as a glycoside in the "Others" pathway category. Eleutheroside C's mode of action involves modulating the hypothalamic-pituitary-adrenal axis and enhancing cellular energy metabolism. It has been investigated for its potential therapeutic and pharmacological effects including anti-inflammatory, anti-fatigue, and antibacterial activities. Not approved for clinical use. |
| Molecular Formula |
C8H16O6
|
|---|---|
| Molecular Weight |
208.2090
|
| Exact Mass |
208.094
|
| CAS # |
15486-24-5
|
| PubChem CID |
9859136
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
395.1±42.0 °C at 760 mmHg
|
| Flash Point |
192.7±27.9 °C
|
| Vapour Pressure |
0.0±2.1 mmHg at 25°C
|
| Index of Refraction |
1.540
|
| LogP |
-2.16
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
14
|
| Complexity |
175
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
CCO[C@@H]1[C@@H]([C@H]([C@H]([C@H](O1)CO)O)O)O
|
| InChi Key |
WYUFTYLVLQZQNH-HNEXDWKRSA-N
|
| InChi Code |
InChI=1S/C8H16O6/c1-2-13-8-7(12)6(11)5(10)4(3-9)14-8/h4-12H,2-3H2,1H3/t4-,5+,6+,7-,8+/m1/s1
|
| Chemical Name |
(2S,3R,4S,5R,6R)-2-ethoxy-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.8028 mL | 24.0142 mL | 48.0284 mL | |
| 5 mM | 0.9606 mL | 4.8028 mL | 9.6057 mL | |
| 10 mM | 0.4803 mL | 2.4014 mL | 4.8028 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
